RxDoctor Payments Data

Tejinder Singh, MD

Neurology · Chapel Hill, NCNPI 1386007193

Payments from drug & device makers

$1,113in general payments, 2019–2025

Across 17 payments — averaging $65.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Neurelis, Inc.$233
  • SK Life Science, Inc.$228
  • Eisai Inc.$118
  • Microtransponder, Inc.$106
  • Lundbeck LLC$103
  • plus $84 from 3 others

What the payments were for

  • Food & beverage$1,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie5$240
Neurelis, Inc.3$233
SK Life Science, Inc.3$228
Eisai Inc.1$118
Microtransponder, Inc.1$106
Lundbeck LLC1$103
UCB, Inc.1$41
Pfizer1$23
Axsome Therapeutics, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,113 in reported general payments places this provider in the 50th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$57,150
Medicare patients
307
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam47$79,975
Emgality PenGalcanezumab-Gnlm53$42,529
VimpatLacosamide38$39,855
UbrelvyUbrogepant21$23,441
Oxtellar XrOxcarbazepine14$23,273
QuliptaAtogepant21$22,845
Nurtec OdtRimegepant Sulfate11$18,739
Aimovig AutoinjectorErenumab-Aooe25$17,988
Levetiracetam378$16,772
Lacosamide134$15,612
Lamotrigine ErLamotrigine24$14,499
Oxcarbazepine60$4,003
Divalproex Sodium ErDivalproex Sodium44$3,634
Lamotrigine185$2,980
Zonisamide58$2,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$41$119,82985 claims
AbbVieUbrelvy, Qulipta$240$46,28642 claims
PfizerNurtec Odt$23$18,73911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 566 neurology providers in North Carolina.

Other neurology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →